Definitive Healthcare vs Health Catalyst
DH and HCAT side by side, both in computer programming, data processing, and other computer related services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How DH and HCAT compare
Definitive Healthcare is the larger company, worth 1.3 times as much as Health Catalyst ($133M against $102M).
Definitive Healthcare grew revenue faster over the last twelve months (−6.2% versus −13.9% for Health Catalyst).
Definitive Healthcare keeps more of each dollar of sales as profit, with a net margin of −69.2% compared with −74.2% at Health Catalyst.
Health Catalyst scores higher on the StockData Score (9 against 5 for Definitive Healthcare), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | DH | HCAT |
|---|---|---|
| Size and price | ||
| Market cap | $133M | $102M |
| Share price | $1.25 | $1.36 |
| Change, 1 year | −56.4% | −49.4% |
| Change, 5 years | −96.4% | −97.1% |
| Beta (5Y) | 1.85 | 1.80 |
| Employees | 686 | 1,200 |
| StockData Score | ||
| Total score | 5 | 9 (better) |
| Valuation score | 3 | 3 |
| Growth score | 0 | 1 (better) |
| Performance score | 0 | 0 |
| Health score | 2 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 0.6× | 0.4× (better) |
| P/B | – | 0.7× |
| P/FCF | 5.5× | 4.0× (better) |
| FCF yield | 18.1% | 25.1% (better) |
| Fair value | $3.97 | $6.03 |
| Margin of safety | 68.5% | 77.5% (better) |
| Growth | ||
| Revenue growth (TTM) | −6.2% (better) | −13.9% |
| Revenue growth, 5Y average | 15.3% (better) | 10.5% |
| Profitability | ||
| Gross margin | 75.4% (better) | 49.1% |
| Operating margin | −105% | −65.7% (better) |
| Net margin | −69.2% (better) | −74.2% |
| FCF margin | 10.6% (better) | 9.4% |
| Return on equity | – | −84.6% |
| Return on invested capital | – | −61.4% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −22.2× | – |
| Current ratio | 1.96 (better) | 1.70 |
| Altman Z-score | −3.25 (better) | −9.10 |
| Piotroski F-score | 5 (better) | 4 |
| Dividends and buybacks | ||
| Buyback yield | 0.00% | 0.00% |
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 81.2% | 69.4% |
| Held by insiders | – | 37.8% |
| Insider net buying, 12 months | – | −$94.9K |
| Short interest, % of float | – | 4.2% |
Go deeper
- DH stock overview
- DH income statement
- DH valuation and score
- HCAT stock overview
- HCAT income statement
- HCAT valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.